Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Deferred Tax (2022 - 2024)

Theravance Biopharma (TBPH) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $2.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $2.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $2.4 million, a N/A change, with the full-year FY2024 number at $2.4 million, changed N/A from a year prior.
  • Long-Term Deferred Tax was $2.4 million for Q4 2024 at Theravance Biopharma, down from $440.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $440.7 million in Q4 2022 to a low of $2.4 million in Q4 2024.